ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI RFAs Available

May 5, 2000

NCI Staff Will Recommend That Comprehensive Recognition Be Withdrawn From Colorado Center

October 31, 1980

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

In Brief: Cancer Program “Strengthened” NIH, Report From Biomedical Research Panel Contends

April 16, 1976

DCT Board Approves New RFA For Aids Clinical Trials Groups

November 11, 1994

Clanton Resigns From NCI.

January 12, 2007